← Oncology Approval Tracker

FDA DECISION ·

Opdivo + fluoropyrimidine and platinum

nivolumab plus fluoropyrimidine- and platinum-based chemotherapy · Bristol Myers Squibb

FDA approvalNew or expanded indicationEsophageal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line use with fluoropyrimidine and platinum chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma.

LAMPGEN ANALYSIS

Why it matters

One of two same-day first-line regimens adds PD-1 inhibition to a chemotherapy backbone.

What research teams should watch

Confirm squamous histology and distinguish chemotherapy-associated and immune-mediated toxicities in study or treatment records.

PRIMARY RECORDS

Sources